Markers of response to zidovudine monotherapy among treated HIV seroconverters

Antiviral Therapy

Volumn 2, Issue 3, 1997, Pages 167-174

  Rezza, Giovanni ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL RATE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; HIV CORE PROTEIN P24; HIV SEROPOSITIVITY; HUMANS; RNA, VIRAL; ZIDOVUDINE;

EID: 0030882157     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Fischl MA, Richman DD, Grieco MH, Gottleib MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan, D, Schooley RT et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS-related complex: a double-blind, placebo-controlled trial. New England Journal of Medicine 1987; 317:185-191.
2. Vella S, Giuliano M, Pezzotti P, Agresti MG, Tomino C, Floridia M, Greco D, Moroni M, Visco G, Milazzo F et al. Survival of zidovudine treated patients with AIDS compared with that of contemporary untreated patients. Journal of the American Medical Association 1992; 267:1232-1236.
3. Moore R, Hidalgo J, Sugland B & Chaisson R. Zidovudine and the natural history of the acquired immunodeficiency syndrome. New England Journal of Medicine 1991; 324:1402-1406.
4. Saah AJ, Hoover DR, He Y, Kingsley LA & Phair JP. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). Jonrnal of Acquired Immune Deficiency Syndromes 1994; 7:287-295.
5. Graham NMH, Zeger SL, Park LP, Vermund SH, Detels R, Rinaldo CR & Phair JR. The effects on survival of early treatment of human immunodeficiency virus infection. New England Journal of Medicine 1992; 326:1037-1042.